Dual action combination

Dual action combination

It is important to remember that Dymista® contains two active ingredients, fluticasone propionate, an intranasal steroid and azelastine an intranasal antihistamine

Antihistamines work quickly to alleviate the immediate symptoms of allergic rhinitis (itching, sneezing, running). Steroids work on the later phase reaction

In addition to azelastine's antihistaminic effects, it has also been shown to have a number of other potentially important attributes, including effects on cytokines, adhesion molecules and inflammatory cells1

Fluticasone propionate is highly selective agonist at glucocorticoid receptor, thereby producing anti-inflammatory and vasoconstriction effects impacting the later phase allergic reaction. Fluticasone propionate in Dymista® exerts a topical effect without systemic side effects due to low bioavailability2

Improved outcomes when using combination products are well accepted and apply to all diseases. Having to take one single device improves compliance and adherence with the medication and patients should be reminded to take Dymista® as directed.

chart

Dymista® spray pattern

The specific formulation and nozzle design of Dymista produces a large fine mist plume

Click to watch video

Further Your Understanding

Click on one of the below links to discover more information about Dymista®, including Flow to use Dymista®, guidelines, clinical papers and request materials.

  • Allergi
    Allergic Rhinitis
  • Impact
    Impact of Rhinitis
  • Impact
    Onset
  • Impact
    Treatment
  • Guidelines
    Guidelines
  • Clinical Papers
    Clinical Papers

References

  1. Horak. Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis Ther Clin Risk Manag 2008 Oct; 4(5): 1009–1022.
  2. Sudding GK, Kariyawasam HH, Scadding G, el al. BSACl guideine for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007) Clin Exp Allergy. 2017;47:856-889.

Want to expand your knowledge…

Register to ViatrisConnect and subscribe to our Allergy newsletters to continue reading.

Viatris Connect

Viatris Connect is an online platform for healthcare professionals. Register today and enjoy this article and a selection of others for free.

REGISTER NOW

Please continue to report suspected adverse drug reactions and device failures with any medicine or vaccine to the MHRA through the Yellow Card Scheme.

It is easiest and quickest to report adverse drug reactions and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, you can report via some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) or by calling the Commission on Human Medicines (CHM) free phone line: 0800-731-6789.
Adverse reactions/events and device failures should also be reported to MAH at e-mail address: pv.uk@viatris.com.

This website is owned and managed by Viatris. For more information visit viatris.co.uk


This site is intended for UK healthcare professionals only. If you're a patient who has been prescribed Dymista® (azelastine hydrochloride/fluticasone propionate), please ​click here.

Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.​

Copyright © 2023 Viatris Inc All rights reserved. Dymista® is a registered trademark of Viatris Inc.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)

Mylan Logo